AncaSt

Noninferiority trials are NOT “no difference” trials. ⚠️ They can be statistically inferior… and still be called “noninferior.” 🤯 Here’s the simplest way to interpret any noninferiority trial like a pro 🧠👇 🧪 Noninferiority = “not substantially worse” ✅ Not about proving equality ✅ Not about “p>0.05 so same” 🎯 Key requirement: The lower bound of the CI must stay above a pre-set margin (Δ) 📌 Why do we even accept this? Because the new treatment may offer: 💊 less toxicity 💰 lower cost 🕒 easier delivery 😌 better QoL But here’s the trap 👇 A treatment can be: ✅ Noninferior AND ❌ Statistically worse than standard 🧠 Biggest mistake in medical Twitter discussions: ❌ “No significant difference → noninferior” ✅ Wrong. Noninferiority needs a margin + CI rule. 🔥 The authors recommend something CRITICAL: ✅ Use TWO margins, not one 1️⃣ Clinical noninferiority vs standard (Δclin) 2️⃣ Efficacy vs no treatment (Δeff) Because even if you’re “close to standard”… you might be no better than placebo 😬 📌 Also important: ⚠️ ITT analysis can be anti-conservative in noninferiority Protocol violations make groups look similar → falsely supports NI ✅ Best practice: report BOTH 🧾 ITT + Per-protocol and require NI in both 🧠 One-liner takeaway: “Noninferior ≠ equivalent ≠ superior.” 📖 Full paper in comment ⬇️ #MedTwitter #OncoTwitter #ClinicalTrials #Biostatistics #EBM @OncoAlert @myesmo @esmo_open @asco